Immunotherapy or antiangiogenic therapy plus chemotherapy as first‐line treatment of patients with PD‐L1 (‐) advanced non‐squamous non‐small cell lung cancer in a Chinese cohort
Cancer Medicine · 2023
DOI: 10.1002/cam4.6101 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Cancer Medicine, 2023. Verfasst von Ruolan Xia und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotherapy, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University Chengdu, Chengdu, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Purpose For patients with advanced nonsquamous non‐small cell lung cancer (NSCLC), immunotherapy or antiangiogenic therapy combined with pemetrexed and cisplatin/carboplatin have both shown significant efficacy at programmed cell death ligand 1 (PD‐L1) levels of
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biotherapy, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University Chengdu, Chengdu, China.
- West China School of Medicine, Sichuan University, Chengdu, China.
- Division of Thoracic Tumor Multimodality Treatment and Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
ORCID-Profile: Meijuan Huang
Zitieren
APA
Xia, R., Li, Y., Yang, L., & Huang, M. (2023). Immunotherapy or antiangiogenic therapy plus chemotherapy as first‐line treatment of patients with PD‐L1 (‐) advanced non‐squamous non‐small cell lung cancer in a Chinese cohort. Cancer Medicine. https://doi.org/10.1002/cam4.6101
Vancouver
Xia R, Li Y, Yang L, Huang M. Immunotherapy or antiangiogenic therapy plus chemotherapy as first‐line treatment of patients with PD‐L1 (‐) advanced non‐squamous non‐small cell lung cancer in a Chinese cohort. Cancer Medicine. 2023. doi:10.1002/cam4.6101
BibTeX
@article{Xia2023,
author = {Xia, Ruolan and Li, Yanying and Yang, Ling and Huang, Meijuan},
title = {Immunotherapy or antiangiogenic therapy plus chemotherapy as first‐line treatment of patients with PD‐L1 (‐) advanced non‐squamous non‐small cell lung cancer in a Chinese cohort},
journal = {Cancer Medicine},
year = {2023},
doi = {10.1002/cam4.6101}
}
EUVIMED